DJIA 18,232.02 0.00 0.00%
NASDAQ 5,089.36 0.00 0.00%
S&P 500 2,126.06 0.00 0.00%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)

company name or ticker
Company Photos
(Click to zoom)

Selling Innate Short

AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog

AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2015 Results - Earnings Call Transcript

Health Care Sector Update for 04/24/2015: CELG, EHTH, AERI

AstraZeneca plc Has a Rocky First-Quarter: Here's What You Need to Know

AstraZeneca reported another tough quarter today, reflecting the loss of exclusivity for top-selling drugs such as Nexium. Even so, there were some important developments and bright spots during the quarter.

European Equities Close the Week Higher as German Business Optimism Grows

Illumina's Earnings Set Positive Tone for Biotech

What's behind Illumina's remarkable earnings beat, and what could it mean for biotech stocks?

Pfizer's Once And Future Deals

Stocks: 6 things to know before the open

Premarkets: 6 things to know before the open

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?

Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?
See More Articles...